Developing software to verify radiation doses during cancer treatment
Tumours and nearby organs can move during radiotherapy, changing where radiation is delivered. Clinicians have limited visibility into the dose actually received during treatment, creating uncertainty about tumour coverage and the exposure of healthy tissue.
Ardos is developing DoseTracker to calculate and verify delivered radiation doses in real time, accounting for patient motion and anatomical changes. The software gives clinicians dose information to identify deviations and guide treatment adjustments.
What stands out about Ardos
Published DoseTracker research validated real-time dose reconstruction against dosimeter measurements on a moving test stage.
Delphinus Venture Capital identifies Ardos as a portfolio company and classifies its initial investment as pre-seed.
Ardos secured a Japanese patent for its dose-guidance technology in July 2026, strengthening protection for its core technology.
The DoseTracker founding research project received BETA.HEALTH grants of DKK 500,000 in its 2022, 2024 and 2025 calls.
Ardos is a spinout from Aarhus University Hospital; Aarhus University's technology-transfer directory dates it to 2022.
Co-founder and CSO Per Poulsen is a medical physics professor with over 20 years of research leadership and co-invented DoseTracker.
DoseTracker was evaluated in 20 prostate-radiotherapy patients: 41 fractions reconstructed online and 50 retrospectively.
Founder Thomas Ravkilde is a clinical medical physicist, software developer and inventor of DoseTracker.
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.